• Home
  •  / Northwest Biotherapeutics

Northwest Biotherapeutics

OverviewSuggest Edit

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments and without the side effects of chemotherapy drugs. The Company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

TypePublic
Founded1998
HQBethesda, USMap
Websitenwbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)17(+22%)
Revenue (FY, 2019)$2.4 M(+485%)
Share Price (Jun 2020)$0.4 (+5%)

Key People/Management at Northwest Biotherapeutics

Marnix L. Bosch

Marnix L. Bosch

Chief Technical Officer
Anthony Maid

Anthony Maid

Senior Vice President - Clinial Research
Show more

Northwest Biotherapeutics Office Locations

Northwest Biotherapeutics has an office in Bethesda
Bethesda, US (HQ)
4800 Montgomery Ln
Show all (1)

Northwest Biotherapeutics Financials and Metrics

Northwest Biotherapeutics Revenue

Northwest Biotherapeutics's revenue was reported to be $2.41 m in FY, 2019
USD

Revenue (FY, 2019)

2.4m

Net income (FY, 2019)

(20.3m)

EBIT (FY, 2019)

(27.5m)

Market capitalization (5-Jun-2020)

253.3m

Closing stock price (5-Jun-2020)

0.4

Cash (31-Dec-2019)

372.0k

EV

270.3m
Northwest Biotherapeutics's current market capitalization is $253.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.0k772.0k809.0k1.5m1.7m623.0k336.0k412.0k2.4m

Cost of goods sold

Gross profit

10.0k772.0k809.0k

Gross profit Margin, %

100%100%100%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

10.0k330.0k120.0k137.0k400.0k582.0k194.0k391.0k291.0k236.0k157.0k159.0k68.0k88.0k148.0k132.0k278.0k453.0k339.0k581.0k593.0k

Cost of goods sold

Gross profit

10.0k330.0k120.0k137.0k

Gross profit Margin, %

100%100%100%100%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

24.0k7.3m18.5m13.4m21.8m6.2m117.0k22.2m372.0k

Prepaid Expenses

94.0k112.0k147.0k387.0k1.4m1.0m1.3m1.6m2.8m

Current Assets

118.0k7.5m18.6m14.6m24.1m7.9m1.4m23.8m3.2m

PP&E

78.0k95.0k83.0k40.0m46.2m315.0k169.0k108.0k281.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

6.7m1.6m37.0k430.0k111.0k373.0k2.0m2.9m12.2m8.9m1.4m3.2m19.2m5.4m11.7m2.1m802.0k1.8m22.0k1.1m198.0k1.6m248.0k16.3m6.7m2.0m

Accounts Receivable

195.0k

Prepaid Expenses

69.0k170.0k79.0k260.0k186.0k39.0k363.0k138.0k147.0k177.0k167.0k666.0k978.0k950.0k1.1m1.5m785.0k923.0k797.0k1.1m931.0k838.0k870.0k2.3m2.2m2.6m

Current Assets

6.8m1.8m116.0k885.0k297.0k412.0k2.3m7.5m12.4m12.4m1.6m4.7m21.2m7.1m13.5m4.5m2.3m3.2m819.0k2.1m1.1m2.4m1.1m18.6m8.9m4.6m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(32.8m)(67.3m)(65.8m)(135.6m)(114.7m)(80.2m)(73.1m)(35.8m)(20.3m)

Depreciation and Amortization

10.0k14.0k11.0k11.0k56.0k189.0k439.0k1.3m21.0k

Accounts Payable

1.4m577.0k766.0k5.0m3.9m1.0m501.0k(436.0k)30.0k

Cash From Operating Activities

(14.7m)(22.8m)(37.8m)(54.6m)(78.6m)(55.7m)(36.5m)(34.6m)(31.9m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(20.7m)(20.3m)(10.2m)(20.3m)(36.8m)(14.4m)(26.0m)(48.9m)(46.0m)(71.9m)(92.9m)(46.4m)(113.3m)(90.7m)(6.1m)(20.3m)(49.5m)(12.6m)(22.9m)(46.1m)(21.5m)(42.7m)(30.1m)(20.9m)(20.7m)(27.0m)

Depreciation and Amortization

4.0k6.0k2.0k4.0k10.0k3.0k6.0k9.0k3.0k6.0k352.0k3.0k15.0k44.0k13.0k80.0k135.0k56.0k100.0k141.0k365.0k722.0k1.1m2.0k8.0k16.0k

Accounts Payable

680.0k1.1m2.0m5.4m10.5m299.0k1.0m1.1m277.0k1.4m3.7m(378.0k)2.2m7.1m(3.1m)628.0k1.7m514.0k3.2m4.4m(628.0k)857.0k4.5m(65.0k)(742.0k)62.0k

Cash From Operating Activities

(5.0m)(10.2m)(3.5m)(8.4m)(14.5m)(7.1m)(15.3m)(23.2m)(10.6m)(27.5m)(36.0m)(17.6m)(44.7m)(56.5m)(17.6m)(31.8m)(41.6m)(12.3m)(16.0m)(21.7m)(4.8m)(16.4m)(20.4m)(9.8m)(19.4m)(25.9m)
show all
USDY, 2019

EV/EBIT

-9.8 x

EV/CFO

-8.5 x

Revenue/Employee

141.8k

Financial Leverage

-0.2 x
Show all financial metrics

Northwest Biotherapeutics Online and Social Media Presence

Northwest Biotherapeutics's Trends

Embed Graph

Northwest Biotherapeutics Company Culture

  • CEO Rating

    F

    50/100

  • Compensation

    F

    10/100

Learn more on Comparably

Northwest Biotherapeutics News and Updates

January 18, 2019

Product Overview and Scope of Worldwide Castration Resistant Prostate Cancer Treatment Market forecast 2025 | TOP Key Players - Active Biotech, Diagnocure, Glaxosmithkline, Northwest Biotherapeutics, Millennium Pharmaceuticals, Hologic, Spectrum Pharmaceu

Summary: A new market study, titled “Discover Global Castration Resistant Prostate Cancer Treatment Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday

Northwest Biotherapeutics Blogs

November 13, 2018

NW Bio Announces $5 Million Bridge Funding

Notes With 50% Warrants Exercisable at $0.35 Per Share BETHESDA, Md., November 13, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it co... The post…
August 29, 2018

Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit

Download the Presentation. View article in Clinical Cancer Research.... The post Dr. Marnix Bosch’s Presentation on Clinical Development of Dendritic Cell-Based Immunotherapy for Cancer at Immuno-Oncology Summit appeared first on Northwest Biotherapeutics.
August 28, 2018

NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit

BETHESDA, Md., August 28, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednes... The post…
June 07, 2018

Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018

View the recorded webcast.... The post Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018 appeared first on Northwest Biotherapeutics.
June 07, 2018

Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018

... The post Webcast: Dr. Marnix Bosch’s Presentation on DCVax® Personalized Dendritic Cell Vaccines from ASCO 2018 appeared first on Northwest Biotherapeutics.
May 31, 2018

NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

BETHESDA, Md., May 31, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the... Th…
Show more

 Northwest Biotherapeutics Frequently Asked Questions

  • When was Northwest Biotherapeutics founded?

    Northwest Biotherapeutics was founded in 1998.

  • Who are Northwest Biotherapeutics key executives?

    Northwest Biotherapeutics's key executives are Marnix L. Bosch and Anthony Maid.

  • How many employees does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 17 employees.

  • What is Northwest Biotherapeutics revenue?

    Latest Northwest Biotherapeutics annual revenue is $2.4 m.

  • What is Northwest Biotherapeutics revenue per employee?

    Latest Northwest Biotherapeutics revenue per employee is $141.8 k.

  • Who are Northwest Biotherapeutics competitors?

    Competitors of Northwest Biotherapeutics include ViroStatics, Jasco Pharmaceuticals and Enochian BioSciences.

  • Where is Northwest Biotherapeutics headquarters?

    Northwest Biotherapeutics headquarters is located at 4800 Montgomery Ln, Bethesda.

  • Where are Northwest Biotherapeutics offices?

    Northwest Biotherapeutics has an office in Bethesda.

  • How many offices does Northwest Biotherapeutics have?

    Northwest Biotherapeutics has 1 office.